Mosaiq

Manufactured by Elekta

Sourced in Sweden, United Kingdom

MOSAIQ is a comprehensive oncology information management system developed by Elekta. It is designed to streamline and optimize clinical workflows, data management, and patient care coordination across various cancer care settings.

Automatically generated - may contain errors

Lab products found in correlation

Versa hd, by Elekta (1 mentions) Big bore ct, by Philips (1 mentions) Statistica, by TIBCO Software (1 mentions) Eclipse treatment planning system, by Agilent Technologies (1 mentions) Pinnacle v 14, by Philips (1 mentions) Brilliance ct big bore, by Philips (1 mentions) Centricity, by GE Healthcare (1 mentions) Linear accelerator, by Siemens (1 mentions)

38 protocols using mosaiq

Acute Skin Toxicity in Radiotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

Demographic data, medical history, clinical characteristics, and tumor characteristics were collected at the first medical visit. Radiotherapy characteristics were collected at the time of prescription of the radiotherapy treatment. Acute toxicity data were collected at weekly follow-up visits during treatment. No toxicity evaluation occurred within 3 months after the end of radiotherapy. All data were collected by systematic data recording on a standardized, computerized form using the MOSAIQ® software (Elekta AB, Stockholm, Sweden).
Demographic data collected were age at the start of radiotherapy and sex. Regarding medical history, we recorded: history of diabetes, menopausal status, active smoking, and body mass index (BMI). Tumor characteristics were TNM classification (American Joint Commission on Cancer 8th edition), hormone and HER2 status, and tumor topography. Radiation therapy characteristics recorded were: CTVs, PTVs treated, total dose, dose per fraction, number of fractions, technique (intensity-modulated radiation therapy (IMRT) or 3D conventional), use of electrons, and energy (MV). Toxicity data collected were only acute skin toxicity.

Bruand M., Salleron J., Guihard S., Crety C.M., Liem X., Pasquier D., Lamrani-Ghaouti A., Charra-Brunaud C., Peiffert D., Clavier J.B., Desandes E, & Faivre J.C. (2022). Acute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort. BMC Cancer, 22, 1318.

+ Open protocol

+ Expand

VMAT Radiation Therapy for Pancreatic Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

This retrospective study was approved by the ethics committee of South Western Sydney Local Health District. The sample consisted of 10 patients who underwent radical VMAT radiation therapy for pancreatic cancer at Liverpool and Macarthur Cancer Therapy Centres between September 2017 and May 2019. Patients required a long course of treatment (25 or more fractions), a planning CT scan acquired with a Philips CT Big Bore (Philips, Eindhoven, The Netherlands), and a complete set of daily cone beam computed tomography (CBCT) images. Dual arc 6MV VMAT treatment plans were created in the treatment planning system (TPS) (Pinnacle, version 16.0, Philips). Each patient was treated on a linear accelerator with on-board CBCT (Elekta Versa HD, Elekta AB, Stockholm, Sweden). The CBCT images were transferred from the online imaging system (XVI, Elekta AB) to the TPS. Each patient’s body mass index (BMI) and initial weight were noted, as registered in the radiation oncology information system (MOSAIQ, Elekta AB). No pretreatment dietary advice was given to patients.

Scott J., Dundas K., Surjan Y., King O., Arumugam S., Deshpande S., Udovitch M, & Lee M. (2021). Quantifying and Assessing the Dosimetric Impact of Changing Gas Volumes Throughout the Course of VMAT Radiation Therapy of Upper Gastrointestinal Tumors. Advances in Radiation Oncology, 6(3), 100650.

+ Open protocol

+ Expand

Retrospective Review of CIED Patients Undergoing RT

Check if the same lab product or an alternative is used in the 5 most similar protocols

A retrospective review of all patients with CIEDs who underwent RT at the five campuses of PeterMac between 2014 and 2018 was performed. Then, data from CIED patients treated with SBRT/SRS, such as patient characteristics, type of CIEDs, irradiation sites, treatment plan specifications, and reports, were extracted from the MOSAIQ (Elekta AB, Stockholm, Sweden) database and Eclipse treatment planning system. Radiation oncologists were also asked to check their medical records and clinical notes to determine if any patients had a CIED malfunction and/or treatment complications during and/or after RT.

Aslian H., Kron T., Watts T., Akalanli C., Hardcastle N., Lonski P., Montaseri A., Hay B., Korte J., Berk K., Longo F, & Severgnini M. (2020). The effect of stereotactic body radiotherapy (SBRT) using flattening filter‐free beams on cardiac implantable electronic devices (CIEDs) in clinical situations. Journal of Applied Clinical Medical Physics, 21(6), 121-131.

+ Open protocol

+ Expand

Bladder Volume Optimization for Prostate Radiotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

In order to determine an appropriate bladder volume range that would satisfy planning constraints, 524 bladder volumes were retrospectively analysed from prostate planning assessment data in our electronic medical record system (Mosaiq^™, Elekta Pty Ltd., North Sydney, Australia) collected across three departments between November 2008 and November 2011. Bladder volumes ranged from 41 mL to 1526 mL, with a mean volume of 321 mL (SD 190 mL). An analysis of the bladder volume versus the number of patients exceeding the V50 < 50 Gy bladder planning constraint8 used in our institute showed an inverse relationship with larger bladder volumes increasingly meeting treatment criteria (Fig. 1). With a target bladder volume of 250–350 mL, the chances of exceeding the V50 < 50 Gy bladder constraint was <5%. Based on these observations this was selected as the target bladder volume range for subsequent work in evaluating and developing the protocol for use of the bladder scanner.

Cramp L., Connors V., Wood M., Westhuyzen J., McKay M, & Greenham S. (2016). Use of a prospective cohort study in the development of a bladder scanning protocol to assist in bladder filling consistency for prostate cancer patients receiving radiation therapy. Journal of Medical Radiation Sciences, 63(3), 179-185.

+ Open protocol

+ Expand

Identifying Metastatic Cancer Patients in ICU

Check if the same lab product or an alternative is used in the 5 most similar protocols

Using a clinical data warehouse of all patients treated at the study
site, an algorithm of International Classification of Diseases, Ninth Revision
codes was used to retrospectively identify all patients with a diagnosis of
metastatic cancer (196.xx, 197.xx, 198.xx) who were admitted to an ICU at a
tertiary care medical center from January 2010—September 2015.^{2 –4 (link)} We used Current Procedural Terminology (CPT)
codes^{5 (link)} to identify
patients who received any RT up to 12 months prior to ICU admission. Two study
investigators reviewed clinical radiation oncology notes and the radiation
oncology record and verify system (Mosaiq^®, Elekta,
Stockholm, Sweden) of each radiation case to confirm the palliative intent and
confirm site of palliative radiation. Reviewers excluded patients who received
curative-intent radiation.

Kruser J.M., Rakhra S.S., Sacotte R.M., Wehbe F.H., Rademaker A.W., Wunderink R.G, & Kruser T.J. (2017). Intensive Care Unit Outcomes Among Patients With Cancer After Palliative Radiation Therapy. International journal of radiation oncology, biology, physics, 99(4), 854-858.

+ Open protocol

+ Expand

Dosimetric Feasibility Study of Glioblastoma RT

Check if the same lab product or an alternative is used in the 5 most similar protocols

For this dosimetric feasibility study, a total of ten patients, who had previously undergone treatment for glioblastoma, were selected from the internal clinical database MOSAIQ® (Elekta, Stockholm, Sweden). The contrast-enhanced T1 and T2 FLAIR weighted magnet resonance imaging (MRI) sequences, the planning computed tomography (CT) scans, and the O-(2-18F-fluoroethyl)-L-tyrosine (FET) positron emission tomography (PET) scans from the primary treatment were utilized to generate two distinct RT treatment plans. The first plan, serving as the reference, was generated following the ESTRO-EANO contouring guidelines of 2023 [25] (link). The second plan was a modified plan generated in accordance with the specific study guidelines outlined for the PRIDE trial.

Bodensohn R., Fleischmann D.F., Maier S.H., Anagnostatou V., Garny S., Nitschmann A., Büttner M., Mücke J., Schönecker S., Unger K., Hoffmann E., Paulsen F., Thorwarth D., Holzgreve A., Albert N.L., Corradini S., Tabatabai G., Belka C, & Niyazi M. (2023). Dosimetric feasibility analysis and presentation of an isotoxic dose-escalated radiation therapy concept for glioblastoma used in the PRIDE trial (NOA-28; ARO-2022-12). Clinical and Translational Radiation Oncology, 45, 100706.

+ Open protocol

+ Expand

Ledderhose Disease Radiotherapy Outcomes

Check if the same lab product or an alternative is used in the 5 most similar protocols

Data collection started after receipt of a completed informed consent letter which was mailed to the patients together with a patient information leaflet. Patient and treatment characteristics were collected through MOSAIQ Ò , the patient management information system of Elekta, used at our department. Information on pain from Ledderhose disease, quality of life, patients' levels of satisfaction and side effects of radiotherapy was collected using questionnaires that were mailed to the patients and then filled out and returned by the patients.

de Haan A., van Nes J.G.H., Werker P.M.N., Langendijk J.A, & Steenbakkers R.J.H.M. (2022). Radiotherapy for patients with Ledderhose disease: Long-term effects, side effects and patient-rated outcome. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 168.

+ Open protocol

+ Expand

Retrospective Study of Patient Data

Check if the same lab product or an alternative is used in the 5 most similar protocols

Patient and treatment related data of patients treated between September 2019 and November 2020 were obtained from the hospital information system (HIS) and the integrated oncology management system MOSAIQ (Elekta AB, Stockholm, Sweden). The data were transferred into a custom-made database (Access, Microsoft, Redmont, USA). After completion of the data collection, data were anonymized and transferred into a Statistical software program for analysis (Statistica, TIBCO Software Inc., 2020. Data Science Workbench, version 14. http://tibco.com).

Rudat V., Shi Y., Zhao R., Xu S, & Yu W. (2023). Setup accuracy and margins for surface-guided radiotherapy (SGRT) of head, thorax, abdomen, and pelvic target volumes. Scientific Reports, 13, 17018.

+ Open protocol

+ Expand

Quantifying Radiation Oncology Physicist Workload

Check if the same lab product or an alternative is used in the 5 most similar protocols

Information from the SCGH Elekta MOSAIQ radiation oncology information system provided data on case numbers. The past year's patient appointment and quality checklist tasks were extracted using Elekta's Crystal Reports tool. Appointment data included the number of CT scans, treatment visits and immobilisation device fitting sessions. Quality checklist data captured all other department tasks recorded in MOSAIQ. Cross-checking the count of selected physics-specific QA activities from MOSAIQ with a separate plan quality metric trend log (maintains historic plan gamma pass rates, physicist comments, etc.) enabled data verification.
ROMP standard work conditions, such as daily hours and annual leave, were obtained from the 'WA Health System -HSUWA -Pacts Industrial Agreement 2022' [8] which covers medical physicists in Western Australia. All equipment or software in the department requiring ROMP time was counted. Physics time per patient case was determined by surveying physicists in the department.

McCallum-Hee B.I, & Mukwada G. (2024). Navigating the 2021 ACPSEM ROMP workforce model: insights from a single institution. Physical and engineering sciences in medicine.

+ Open protocol

+ Expand

Automated Couch Position Tracking in Radiotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

Self-developed software was used in the Elekta MOSAIQ network (Elekta Oncology Systems, Crawley, UK) to acquire the couch-position data for each treatment cycle on the Synergy accelerator. Three directions (X, Y, and Z) were included: +X and –X represented the patient’s left and right, +Y and –Y represented the cranial-caudal direction (the beam and target ends of the accelerator), and +Z and –Z represented the ventral-dorsal (rising and falling directions of the accelerator couch). At the end of the radiotherapy, a total of 25 datasets were acquired for each patient in the 3 directions. The primary setup, which was completed by a team composed of a radiation oncologist, a radiation physicist and a technologist, was similar to the position at CT simulation due to the short time interval; thus, the couch position of the first therapy course was used as the baseline. The subsequent 24 couch-position datasets were compared with the baseline to generate the couch-position deviation for each therapy course and the mean deviation for the 25 fractions (Δx, Δy, Δz). The total couch-position deviation (S, cm) was calculated as:

Yang Y., Cai S., Zhao T., Peng Q., Qian J, & Tian Y. (2020). Effect of prone and supine treatment positions for postoperative treatment of rectal cancer on target dose coverage and small bowel sparing using intensity-modulated radiation therapy. Translational Cancer Research, 9(2), 491-499.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!